---
figid: PMC10532419__ijms-24-14405-g004
pmcid: PMC10532419
image_filename: ijms-24-14405-g004.jpg
figure_link: /pmc/articles/PMC10532419/figure/ijms-24-14405-f004/
number: Figure 4
figure_title: ''
caption: Targets of secreted LOXL2. LOXL2 provokes ECM remodelling, activating the
  FAK signalling pathway in fibroblasts and tumour cells. Additionally, it stimulates
  the AKT and ERK signalling pathways specifically in tumour cells. LOXL2 oxidises
  PDGFRβ, enhancing ERK signalling in fibroblasts, and increases the secretion of
  lymphangiogenic factors (VEGFC and SDF-1α). In distant organs, secreted or exosomal
  LOXL2 stimulates the formation of premetastatic niche.
article_title: 'LOXL2 in Cancer: A Two-Decade Perspective.'
citation: Amparo Cano, et al. Int J Mol Sci. 2023 Sep;24(18):14405.
year: '2023'

doi: 10.3390/ijms241814405
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- LOXL2
- human tumour sample
- regulation
- targets
- mouse models
- tumour progression

---
